Drug and Therapeutics Committee

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Common/shared responsibilities between jobs.
Biopharmaceutical Quality
Medication Management
Drug and Therapeutics Committee Session 5. Pharmaceutical Quality Assurance.
Bioequivalence Studies Anoop Agarwal
GMP Document and Record Retention
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
World Health Organization
Overview on Drug Quality and Drug Standard Sompol Prakongpan, Ph.D. Faculty of Pharmacy, Mahidol University 26 March 2010.
The concept of Quality ● Quality means those features of products which meet customers needs and thereby provide customer satisfaction. This meaning is.
Management of Medicines and Pharmaceutical Supplies for use in the prevention and treatment of Pre-eclampsia and Eclampsia Grace Adeya, SPS/MSH February.
Quality control of raw materials In-process control
Reference, Retention and Reserve Samples
Inventory Management: Distribution, ICS, LMIS Nairobi, 21 February, 2006 Yasmin Chandani HIV/AIDS Technical Coordinator.
Drug and Therapeutics Committee Session 7A. Identifying Problems with Medicine Use: Indicator Studies.
Training Course on Managing Medicines and Pharmaceutical Supplies for Tuberculosis.
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Good Manufacturing Practices for Blood Establishments
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Post approval changes- Variations Mercy Acquaye. Presentation Outline Introduction to Guidance Classification of changes Approval of changes Definitions.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Tanzania, August, 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Guidelines and Tools available TRS 937 and BTIF (Bioequivalence Trial Information Form)
World Health Organization
Quality Control Testing in Procurement Helene Möller, M.Pharm, PhD Interregional Seminar for Quality Control Laboratories involved in WHO Prequalification.
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
GMP on blood/plasma collection establishments Group 2.
Important informations
1 Department of Medicines Policy and Standards, Health Technology and Pharmaceuticals WHO’s Role in Assuring the Quality Safety and Efficacy of Medicines:
Demonstrably Difficult to Compound Drug Products Kathleen Anderson, Pharm. D. Division of Prescription Drug Compliance and Surveillance Office of Compliance.
BNF for children and formulations Ian Costello British National Formulary.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Abstract Impact of the Essential Drugs Programme at the Primary Health Care Level in South Africa Hela M, Zeeman H, Department of Health South Africa;
Compounding Kenneth Schell Pharm. D President, CA State Board of Pharmacy.
Dispensary and Administration Site Information Presentation.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Solid dosage forms Tablets
Quality Assurance of Medicines under Universal Health Coverage Program by Siriwat Tiptaradol (Presenter) Duangporn Abhigantaphand Sooksri Ungboriboonpisal.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
Quality Control significance in pharmaceutical industry
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
Inventory Management Chapter 13.
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
Nonsterile compounding-USP ch 795
Solid dosage forms Tablets
QUALITY ASSURANCE AND QUALITY CONTROL IN GENERICS
HHM 5014 NUTRACEUTICAL FORMULATION TECHNOLOGY
Quality Assurance and Quality Control in Generics
QUALITY ASSURANCE OF PHARMACEUTICAL PRODUCTS IN RMH
Lesson 5: BRITE Seminar: GMP II
Food Production Systems
Nonsterile compounding-USP ch 795
Introduction to GMP.
Nonsterile compounding-USP ch 795
GMP Inspection Process
GMP Inspection Process
World Health Organization
Selected Bioavailability and Pharmacokinetic Calculations
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
Inventory Management: Distribution, ICS, LMIS
Ch 18: Pharmacy.
Prequalification of HIV/AIDS products and manufacturers
8 Medication Errors and Prevention.
Compounded Drugs and Lack of Premarket FDA-Approval
Presentation transcript:

Drug and Therapeutics Committee Session 5. Pharmaceutical Quality Assurance

Acknowledgment Material for this session is adapted from Chapter 18, “Quality Assurance for Drug Procurement,” of Managing Drug Supply 2nd ed. Management Sciences for Health and World Health Organization, 1997.

Objectives Define medicine quality Understand how medicine quality is assessed Understand how medicine quality is ensured Describe the role of the DTC in pharmaceutical quality assurance

Outline Key definitions Introduction Determinants of medicine quality How is quality assessed? How is quality assured? Important pharmaceutical quality issues for the DTC Implications for the DTC

Key Definitions (1) Pharmaceutical quality assurance (QA)—Sum of all activities and responsibilities required to ensure that the medicine that reaches the patient is safe, effective, and acceptable to the patient Pharmaceutical quality control—Process concerned with medicine sampling, specifications, and testing, and with the organization’s release procedures that ensure that the necessary tests are carried out and that the materials are not released for use, nor products released for sale or supply, until their quality has been judged satisfactory

Key Definitions (2) Good Manufacturing Practices (GMP)—Performance standards that WHO and many national governments established for pharmaceutical manufacturers covering, for example, personnel, facilities, packaging, and quality control. GMPs are part of the quality assurance activities that ensure that products are consistently produced and controlled to the quality standards appropriate to their intended use and required by the drug regulatory authorities.

Introduction: Goals of Medicine QA Programs To make certain that each medicine reaching a patient is safe, effective, and of standard quality Obtaining quality products that are safe and effective through structured selection and procurement methods Maintaining quality products through the appropriate storage, distribution, monitoring, and use by prescribers, dispensers, and consumers

Characteristics of a Comprehensive QA Program (1) Medicines are selected on the basis of safety and efficacy, in an appropriate dosage form with the longest shelf life Suppliers with acceptable quality standards are selected Medicines received from suppliers and donors are monitored to meet quality standards Medicine packaging meets contract specifications

Characteristics of a Comprehensive QA Program (2) Repackaging activities and dispensing practices maintain quality Adequate storage conditions in all pharmaceutical areas are maintained Transportation conditions are adequate Product quality concerns are reported and monitored

Impacts of Low-Quality Medicines § Lack of therapeutic effect: Prolonged illness Death Toxic and adverse reaction Waste of limited financial resources Loss of credibility ? MEDICINE QUALITY

Determinants of Medicine Quality Identity: Active ingredient Purity: Not contaminated with potentially harmful substances Potency: Usually 90–110% of the labeled amount Uniformity: Consistency of color, shape, size Bioavailability: Interchangeable products? Stability: Ensuring medicine activity for stated period Identity, purity, potency, uniformity are defined in pharmacopoeias and stated in certificate of analysis (COA)

Potential Bioavailability Problems Aminophylline Ampicillin Carbamazepine Chloroquine Digoxin Dihydroergotamine Ergotamine Erythromycin Estrogens Furosemide Glibenclamide Glyceryl trinitrate Iron sulfate Isosorbide dinitrate Levodopa Levothyroxine Methyldopa Nitrofurantoin Phenytoin Prednisolone Prednisone Quinidine Rifampicin Spironolactone Theophylline Warfarin Medicines with narrow therapeutic range Slow-release formulations New formulations (e.g., rectal paracetamol)

Standard Method for Bioavailability Studies Subject: adult, healthy, nonsmoker, nondrinker Design: cross-over, 12–14 subjects Medicine administration: overnight fast, single dose Serial blood sampling: minimum 3 T1/2 Medicine assay in plasma Parameters: Cmax Tmax AUC0- Judgment for bioequivalency: <20% difference 1 10 100 2 4 6 8 12 14 16 18 20 22 24 C T

Rifampicin 450 mg Capsules: > 100% Variation among Brand Names 5 10 15 20 25 2 4 6 8 12 14 16 18 22 24 Time (hours) Originator Plasma RMP concentration (mcg/ml) Source: Suryawati (1992)

Captopril 25 mg: Variation among Brand Names N = number of studies

Nifedipine 20 mg: Generic vs. Brand Name Plasma concentration (ng/ml) 180 Generic 160 Brandname 140 120 100 80 60 40 20 1.5 3 4.5 6 7.5 9 10.5 12 13.5 15 16.5 18 19.5 21 22.5 24 Time (hours) Source: Suryawati and Santoso (1995).

Slow-Release Diclofenac Tablet Plasma concentration (ng/mL) 20 40 60 80 100 120 1 2 3 4 5 6 7 8 9 10 11 12 Imported product MEC = 20 ng/mL Time (hours) Source: Suryawati (1989).

Medicines with a Stability Problem Tablets: Acetylsalicylic acid Amoxicillin Ampicillin Penicillin V Retinol Oral liquids: Paracetamol Injectable: Ergometrine Methylergometrine Select the most stable formulation with adequate packaging

How Is Quality Assessed? INSPECTION of products on arrival Visual inspection Product specification review (including expiration dates) LABORATORY TESTING for compliance with pharmacopoeial standards International Pharmacopoeia European Pharmacopoeia U. S. Pharmacopeia British Pharmacopoeia National Pharmacopoeia BIOAVAILABILITY DATA 1 COA 3 2

How Is Medicine Quality Assured? (1) Product selection Long shelf-life Acceptable stability Acceptable bioavailability Selection of appropriate suppliers Supplier pre-qualification Request samples from new suppliers Request specific reports and data for certain medicines (e.g., bioavailability and stability studies) Collect and maintain information on supplier performance Product certification GMP certificate of manufacturer Product/batch certification (COA) Random local testing

How Is Medicine Quality Assured? (2) Contract and procurement specifications Pharmacopeia reference standard Local language for product label Standards for packaging to meet specific storage and transport conditions

How Is Medicine Quality Assured? (3) Appropriate storage, transport, dispensing, and use procedures Pharmaceutical distribution and inventory control procedures Provision for appropriate storage and transport including adequate temperature control, security, and cleanliness Explicit enforcement of cold chain procedures Appropriate dispensing: containers, labeling, counseling Avoidance of repacking unless quality control in place

How Is Medicine Quality Assured? (4) Product monitoring system Problem reporting: who, how, where, and to whom; what additional measures; what follow-up information Product recalls: hospital or country level

Who Ensures Medicine Quality? Drug regulatory authority

Implications of Pharmaceutical QA for the DTC Providing technical advice on procurement of pharmaceuticals Defining product specifications Generic medicines Bioavailability issues Stability issues Defining minimum laboratory testing Providing technical advice to hospital departments Medicine transportation and storage Dispensing Analyzing product problem reports Quality complaints Medicine recall system

Activity (30 minutes) Pharmaceutical quality assurance issues and concerns on— Obtaining quality products Maintaining quality products Examples of poor quality Discussion Are you satisfied with the quality of medicines you receive? Is quality maintained throughout your distribution network? Are there complaints of poor quality by patients or health workers? Is there a formal mechanism for reporting and investigating complaints? What role do you see for the DTC in improving and maintaining quality in your health care system? at hospital level

Summary (1) Ensuring quality of a product from selection to use— Obtaining quality products that are safe and effective through structured selection and procurement methods Maintaining quality products through appropriate storage, distribution, monitoring, and use methods

Summary (2) Assessing quality includes— Inspection of medicines Laboratory testing when necessary

Summary (3) Assuring quality includes— Selection of medicines, dosage forms, and packaging Use of prequalified suppliers Product certification Preparation and enforcement of quality-related contract specification Appropriate storage, transport, dispensing, and use Product monitoring systems